ADI-270

ADI-270 is a CAR-T cell therapy developed by Adicet Therapeutics. Its target is CD70 (the sponsor names CD70). The sponsor states: An armoured, allogeneic 'off-the-shelf' CAR gamma-delta (CAR-γδ) T-cell therapy directed against CD70-expressing cells, with reported CAR-directed and CAR-independent anti-tumour activity against solid and haematologic malignancies. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in renal cell carcinoma. The largest, NCT06480565, plans to enrol 60 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.